arzoxifene hydrochloride
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Nov 1, 1998 → Apr 1, 2001
NCT ID
NCT00003669About arzoxifene hydrochloride
arzoxifene hydrochloride is a phase 2 stage product being developed by Eli Lilly for Endometrial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00003669. Target conditions include Endometrial Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00003669 | Phase 2 | Completed |
| NCT00003670 | Phase 2 | Completed |
Competing Products
20 competing products in Endometrial Cancer